Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients by Kim, Dae Il et al.
DOI: 10.3345/kjp.2010.53.12.1000 
Korean J Pediatr 2010;53(12):1000-1005
Original article
1000
Therapeutic monitoring of vancomycin according to 
initial dosing regimen in pediatric patients
Purpose: This study aimed to determine the optimal initial vancomycin 
dose to achieve appropriate trough levels in pediatric patients.
Methods: We analyzed clinical data for 309 children treated with 
intravenous vancomycin between 2004 and 2009 at 2 different 
hospitals in South Korea. The patients were 1-16 years old and 
exhi  bited normal renal function. Patient data, including reason for 
treatment and initial dosing regimen, were reviewed. Two subgroups 
were identified and compared according to initial vancomycin dose: 
40 (35-45) mg/kg/day and 60 (55-65) mg/kg/day. Trough levels were 
obtained at steady state after at least 4 doses of vancomycin.
Results: Patients who received vancomycin had post-operation or 
wound-related infections (37.2%), localized infection (12.9%), catheter-
related infections (9.4%), meningitis (8.7%), or endocarditis (6.8%). 
Pathogens were confirmed in 79 cases: 28 cases of methicillin-
resistant Staphylococcus epidermidis (35.4%) and 25 of methicillin-
resistant Staphylococcus aureus (31.6%). Out of the 309 patients, 201 
(65%) received vancomycin at 40 mg/kg/day and 108 (35%) at 60 
mg/kg/day. Average trough concentrations were significantly different 
between the groups (P<0.001). Trough levels over 10 mg/L were less 
likely to be achieved in the 40 mg/kg/day group (14%) than in the 60 
mg/kg/day group (49%) (P<0.001). There were no differences in renal 
function deterioration between the groups. 
Conclusion: A common vancomycin dosing regimen, 40 mg/kg/
day, was not high enough to achieve trough levels of over 10 mg/L in 
pediatric patients. Careful drug monitoring must be performed, and 
increasing initial dose of vancomycin should be considered in pediatric 
patients.
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has increased with the emergence of methicillin-resistant 
Staphylococcus aureus (MRSA)
1, 2). A recent report regarding 
increase of vancomycin minimal inhibitory concentration (MIC) 
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documented treatment failures associated with heterogeneous-
vancomycin intermediate S. aureus (hVISA)
3, 4). Despite limitations 
including poor tissue penetration (particularly in the lung), 
rela  tively slow bacterial killing, and the potential for toxicity
5), 
vancomycin is regarded as the gold-standard for antibiotic 
treatment of MRSA infections due to its low cost and established 
clinical response
6). 
Major pediatric dosing references for vancomycin recommend a 
daily dose of 40 mg/kg/day for empiric therapy, while a dose of 60 
mg/kg/day is recommended for central nervous system infections
7, 
8). In adults, the recommended daily dose is 1 g every 12 hours and 
the recommended trough level is 5 to 10 mg/L
9, 10) or 5 to 15 mg/
L
11). 
However, a review recently published by the American Society 
of Health System Pharmacists (ASHP), the Infectious Diseases 
Society of America (IDSA), and the Society of Infectious Disease 
Pharmacists (SIDP) recommended a daily vancomycin dosage of 
15 to 20 mg/kg every 8 to 12 hours (based on actual body weight, 
including obese patients) and maintaining a vancomycin trough 
concentration between 15 and 20 mg/L for treatment of bacteremia, 
endocarditis, osteomyelitis, meningitis, and pneumonia
12). The 
purpose of the present study is to evaluate the adequacy of the 
recommended initial dosage of vancomycin in pediatric patients by 
analyzing serum trough levels after the initial dosage.
 Materials and methods
1. Study sample 
We collected medical records data for children who were treated 
with intravenous vancomycin therapy for at least five days between 
January 2004 and September 2009 at Seoul National University 
Hospital and Seoul National University Bundang Hospital, Seoul, 
Korea, for this retrospective observational study.
1) Inclusion criteria were
(1) age between 12 months and 16 years; (2) duration of 
vancomycin infusion ≥5 days; (3) normal renal function; (4) trough 
level of initial steady state (after at least 4 dose infusion and first data 
of multiple therapeutic drug monitoring (TDM) data in admission 
period), and (5) vancomycin dosage range between 35 and 65 mg/
kg/day.
2) Exclusion criteria were
(1) abnormal renal function and (2) dosage that was either too 
low (<35 mg/kg/day) or too high (>65 mg/kg/day). Abnormal renal 
function patients were defined as patients previously diagnosed with 
renal disease such as acute renal failure (ARF), chronic renal failure 
(CRF), or end stage renal disease, or who exhibited abnormal serum 
creatinine levels for age on the day of initial vancomycin infusion. 
2. Review of medical records
Information regarding vancomycin dosage and administration, 
duration of infusion, trough level, time that the trough level was 
sampled, diagnosis, culture results, and concomitant other drug 
therapy was collected by a review of medical records. Demographic 
data were also collected, including age, sex, weight, and data of 
serum creatinine, and any other underlying diseases were collected. 
3. Statistical analysis
In univariate analyses, categorical variables were compared using 
the chi-square test and continuous variables were compared using 
the t-test between the two dosage groups. Independent t-tests were 
also used to compare the mean trough levels between the 40 mg/
kg/day and 60 mg/kg/day regimens. Pearson’s correlation tests were 
used to detect correlations between vancomycin trough levels and 
dosages. P-values <0.05 were considered statistically significant. All 
analyses were performed using SPSS version 17.0.
Results
1. Patient characteristics
The medical records of 502 patients were reviewed, and data for 
309 patients were analyzed after exclusions. The mean patient age 
was 7.62 years and the mean duration of vancomycin infusion was 
21.5 days. The patients were divided into two groups. Group A 
included 201 patients (65%) who received 40 (35-45) mg/kg/day of 
vancomycin. Group B included 108 patients (35%) who received 
60 (55-65) mg/kg/day of vancomycin. 
During the study period, vancomycin was recommended 
to use initial dose of 60 mg/kg/day for the treatment of central 
nervous system infections, serious infections in cancer patients, or 
Table 1. The Underlying Diseases of the Patients
Underlying diseases
Initial dose of vancomycin, No. (%)
40 mg/kg/day 60 mg/kg/day
None
Hemato-oncological
Cardiac
Immune deficiency
Neurologic
Others*
22 (11.4)
50 (26.0)
67 (34.8)
12 (  6.2)
13 (  6.8)
28 (14.6)
10 (  8.6)
52 (44.4)
12 (10.3)
28 (23.9)
10 (  8.5)
5 (  4.3)
*Others are endocrine disease (as DM), metabolic disease, rheumatic 
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patients who need vancomycin in critical conditions
7, 8). Otherwise, 
vancomycin was used in initial dose of 40mg/kg/day to treat 
infectious diseases in patients with normal renal function. A total 
of 277 patients (89.6%) had underlying diseases such as hemato-
oncological diseases, cardiac diseases, and immune deficiencies 
(Table 1). 
Demographic data of the patients are presented in Table 2. There 
was no significant difference between the patient groups except 
concomitant use of rifampicin and diuretics.
Gender, age, body weight, time of trough level sampling, dura-
tion of infusion, administration interval (every 6 hours or every 8 
hours), initial creatinine level, concomitant use of aminoglycosides 
and use of non-steroidal anti-inflammatory drugs (NSAIDs) 
were not significantly different between group A and group B. 
Concomitant use of rifampin was more frequent in group B (16.7%) 
than in group A (2.9%) (P=0.002), while concomitant use of 
diuretics was more frequent in group A (24.9%) than in group B 
(10.1%) (P=0.025).
In all patients, vancomycin was administered to treat post-
operative fever (20.7%), wound infection (16.5%), localized 
infections such as abscesses or skin infections (12.9%) and 
bacteremia (9.4%) or meningitis (8.7%). The indications for which 
all patients were administered vancomycin are presented in Table 3. 
The infectious pathogen was identified in 79 cases. Of these, 28 
cases were diagnosed with methicillin-resistant Staphylococcus 
epidermidis (MRSE) (35.4%) and 25 cases with MRSA (31.6%).
2. Vancomycin dosages
Vancomycin trough levels and initial vancomycin doses were 
correlated in the total patient sample as shown in Fig. 1 (P=0.000). 
The mean vancomycin trough level was 6.58±3.52 mg/L (range, 1.3 
to 18.4 mg/L) in group A and 12.17±6.34 mg/L (range, 2.3 to 63.1 
mg/L) in group B. The mean trough level was significantly lower in 
group A than in group B (P=0.000).
The distribution of trough level differed significantly according to 
initial vancomycin dose (Table 4). In group A, 77 patients (38.3%) 
Table 2. Demographic and Clinical Data of the Patients
Parameters
Initial dose of vancomycin (%) P-
value 40 mg/kg/day 60 mg/kg/day
Age (years)
Gender
  Male 
Body weight (kg, mean±SD)
Time of sampling
(No. of infusion, mean±SD)
Duration of vancomycin use
(days, mean±SD)
Administration
Every 12 h
Every 8 h
Every 6 h
Concomitant drugs
Aminoglycosides
Rifampin
Diuretics
NSAID 
Initial creatinine level 
  (mg/dL, mean±SD)
7.55±4.53
113 (58.9)*
26.2±15.3
18.9±16.9
19.0±15.4
25 (13.0)
26 (13.6)
141 (73.4)
37 (18.4)
6 (  2.9)
50 (24.9)
104 (51.7)
0.55±0.19
7.56±4.59
73 (62.4)
25.9±13.8
23.3±22.0
23.3±23.7
0 (     0)
20 (17.0)
97 (83.0)
27 (   25)
18 (16.7)
11 (10.1)
61 (56.5)
0.5±0.19
0.905
0.625
0.911
0.163
0.180
0.813
†
0.308
0.002
0.025
0.543
0.075
Abbreviations: SD, standard deviation; NSAID, Non-steroidal anti-
inflammatory drug
*Values are expressed as No. (%) unless specified otherwise.
†The data are analyzed with every 8 hours interval and every 6 
hours interval (excluding every 12 hour interval).
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Fig. 1. Scatterplot of vancomycin initial dose (x-axis) and trough level 
(y-axis). The Pearson coefficients=0.28 (P=0.000).
Table 3. The Clinical Indication for Initial Vancomycin Infusion
Clinical indications No. of patients (%)
Post-operation fever 
Wound infection 
Localized infection 
Bacteremia, catheter-related infection 
Meningitis                            
Endocarditis 
Neutropenic fever 
Prosthesis related infection 
Pneumonia 
Chronic otitis media 
Others*
Total
64 (20.7) 
51 (16.5) 
40 (12.9) 
29 (  9.4) 
27 (  8.7) 
21 (  6.8) 
21 (  6.8) 
18 (  5.8) 
14 (  4.5) 
12 (  3.9) 
12 (  3.9) 
309 (100)
*Others are fever of unknown origin, lymphadenitis, pseudomembranous 
colitis, etc.
Table 4. Distribution of Trough Level
Initial dose of 
vancomycin
Trough level (mg/L), No. (%)
Total
< 5 5-10 10-15 >15
40 mg/kg/day
60 mg/kg/day
77 (38.3)
13 (12.0)
96 (47.7)
42 (39.0)
20 (10.0)
31 (28.7)
  8 (  4.0)
22 (20.3)
201 
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had trough levels <5 mg/L, 96 patients (47.7%) had trough levels 
5-10 mg/L, 20 patients (10%) had trough levels 10-15 mg/L, and 
only eight patients (4%) had trough levels >15 mg/L. In group B, 22 
patients (20.3%) had trough levels >15 mg/L, 31 patients (28.7%) 
had trough levels 10-15 mg/L, 42 patients (39%) had trough levels 
5-10 mg/L and only 13 patients (12%) had trough levels <5 mg/L. 
In group A, 28 patients (14%) achieved trough levels over 10 mg/L, 
while in group B, 53 patients (49%) achieved trough levels over 10 
mg/L, difference that was statistically significant (P<0.001).
There were no differences in deterioration of renal function 
between the groups (P=0.609). The creatinine levels of four patients 
in group A (0.02%) and three patients in group B (0.028%) were 
higher than normal according to age after vancomycin infusion, but 
all of these cases normalized after administration of vancomycin 
was ceased. All seven patients were concomitantly treated with 
other nephrotoxic drugs, including aminoglycosides and diuretics.
Discussion
In this study, we investigated the relationships between vanco-
mycin trough concentrations and initial vancomycin dose in 
309 pediatric patients with normal renal function. Patients who 
received dosages of 40 mg/kg/day exhibited mean trough levels that 
were lower (6.58±3.52 mg/L) than those of patients who received 
60 mg/kg/day (12.7±6.34 mg/L), and the proportion of patients 
maintaining trough levels >10 mg/L was also lower among patients 
receiving 40 mg/kg/day (14% of group A vs. 49% of group B). 
Vancomycin has been used as the primary therapeutic agent 
to treat MRSA infections for the past 40 years in both adults 
and children
13). Although several recent reports have highlighted 
the limitations of vancomycin, which include relatively slow 
bactericidal activity, the development of resistance and associated 
therapeutic failure, poor tissue penetration, and the potential for 
serious toxicity
5, 14), and newer anti MRSA medications show great 
promise, vancomycin is well-tolerated and is still the drug of choice 
to empirically treat all types of MRSA infection
1, 15). Until recently, 
vancomycin was usually administered intravenously to adults at a 
dosage of 1 g every 12 hours, with the targeted serum trough level 
set between 5 and 10 mg/L
9, 10, 16, 17).
Although the American Thoracic Society advises that van-
comycin should be given in doses sufficient to achieve a trough 
level between 15 to 20 mg/L for the treatment of MRSA pneu-
monia because of the emergence of MRSA strains with reduced 
susceptibility to vancomycin, the optimal doses and trough 
levels in adults remain controversial due to pharmacokinetic and 
pharmacodynamic properties of vancomycin
18), lack of well designed 
randomized clinical evaluations, and lack of data to support a clear 
relationship between specific serum concentrations and patient 
outcome. However, a recent consensus review on thera  peutic 
monitoring of vancomycin recommended maintaining van  comycin 
trough concentration between 15 and 20 mg/L for bacteremia, 
endocarditis, osteomyelitis, meningitis, and pneumonia
12). 
The area-under-the-concentration-time-curve (AUC) divided 
by the MIC (AUC/MIC) best predicts treatment outcomes when 
treating invasive MRSA infections with vancomycin in adults, and 
an AUC/MIC values >400 for vancomycin are associated with 
optimal outcomes in the treatment of adults
19, 20). For pathogens 
with MICs of 1 mg/L, the minimum trough serum vancomycin 
concentration would have to be at least 15 mg/L to obtain this 
target AUC/MIC
12). Vancomycin dosages of 15-20 mg/kg given 
every 8-12 hours are required for most adult patients with normal 
renal function to achieve the suggested serum concentrations when 
the MIC is ≤1 mg/L
12). 
Some data suggest that low serum levels of vancomycin early in 
the treatment course of MRSA infections may also be associated 
with the emergence of VISA and hVISA
20, 21). Howden et al.
22) 
suggested that not only previous MRSA infection and glycopeptide 
exposure, but trough serum vancomycin concentrations of <10 
mg/L may predict therapeutic failure and the potential for the 
emergence of VISA or vancomycin-resistant Staphylococcus aureus 
(VRSA). For this reason, it is recommended that trough serum 
vancomycin concentrations always be maintained above 10 mg/L 
to avoid development of resistance by consensus review
12).
In pediatric patients, until recently the recommended daily dose 
of vancomycin was 40 mg/kg/day for common infections, while a 
dose of 60 mg/kg/day was recommended for serious infections such 
as central nervous system infections. The recommended trough 
level was 5-15 mg/L, as in adult patients
7, 8).  
In a previous study
23) of infants and children treated for suspected 
staphylococcal infections, vancomycin was administered in total 
dose of 40 mg/kg/day divided into four doses of 10 mg/kg/day every 
6 hours. This regimen achieved goal trough levels (5-15 mg/L) in 
only 45% of 31 control patients. In 33 patients with malignancies, 
88% required doses of 60 mg/kg/day to achieve goal trough levels. 
In another study
24), 76 pediatric intensive care unit patients with 
normal renal function required a mean dose of 60 mg/kg/day to 
achieve a mean trough level of 7.8 mg/L. These data support the 
contention that a starting vancomycin dose of 40 mg/kg/day may 
not be optimal to achieve recommended trough levels in children.
Recently, in a study
15) in which pediatric patients received 
vancomycin doses of 40 mg/kg/day, the AUC/MIC target of 400 
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For MRSA isolates with MIC 1.0 g/mL, the AUC/MIC was always 
<400 at this dose, suggesting that empiric treatment of invasive 
MRSA infections in children should implement vancomycin doses 
of 60 mg/kg/day.
We observed that the mean vancomycin trough level in group 
A was far short of the recommended trough levels (>10 mg/L) for 
adults that are required to avoid development of resistance. The 
results of the present study imply that an initial vancomycin dose 
40 mg/kg/day, which is the current standard recommended dose 
for pediatric patients, may not yield optimal therapeutic effects or 
prevent the development of antibiotic resistance. However, given 
only this result, it is too early to confirm that the recommended 
initial dose of vancomycin for pediatric patients should be higher. A 
prospective study is warranted exploring the influences of the initial 
dose of vancomycin and trough levels on the therapeutic results 
when treating MRSA infections.  
This study had several limitations. First, this was a retrospective, 
observational single center study. Second, we did not evaluate AUC 
or the MIC because these data were not available for all patients. 
However, increased serum trough levels are associated with greater 
AUCs and serum trough levels are considered adequate surrogate 
markers for AUC, although serum trough levels do not directly 
reflect AUC. Third, most patients treated with vancomycin had 
underlying diseases (88.3%), and there were relatively few cases for 
which the pathogen was microbiologically confirmed (79 cases, 
25.6%) of the confirmed cases, only 66.7% were cases of MRSA or 
MRSE. Therefore we were unable to evaluate microbiological and 
clinical therapeutic effects of initial vancomycin doses and trough 
levels. Concomitant use of diuretics such as furosemide were more 
frequently observed in patients receiving usual dosages (40 mg/kg/
day) of vancomycin, and furosemide may influence vancomyin 
trough levels
25-27).  
On the other hand, some data indicate that there are no benefits 
of high dose strategies. Jeffres et al.
28) retrospectively evaluated 
102 patients with health-care-associated MRSA pneumonia and 
observed no significant differences in mean vancomycin trough 
levels or AUC between survivors and nonsurvivors. Similarly, 
Hermsen et al.
6) retrospectively evaluated 55 patients with pneu-
monia, osteomyelitis, and endocarditis and also observed no 
signi  ficant differences in clinical outcomes between patients who 
achieved high trough levels (≥15 mg/L) and those with low trough 
levels (<15 mg/L).
Some published studies report significant associations between 
increased vancomycin trough concentrations and nephrotoxicity
6, 
29). However, current consensus is that the nephrotoxic risk of 
vancomycin is minimal in patients without risk factors for ne-
phrotoxicity, and the relationship of between vancomycin 
trough concentrations and nephrotoxicity remains controversial 
because patients receiving aggressive dosing are more likely to 
receive concomitant nephrotoxins and have other risk factors 
for nephrotoxicity
1). In our study, we did not observe significant 
association between high initial vancomycin dose and nephrotoxicity. 
In conclusion, we observed that traditional recommended 
doses of vancomycin in pediatric patient (40 mg/kg/day) was 
insufficient to achieve recommended trough levels for therapeutic 
effect (5-10 mg/L). However, before recommending increases in 
the initial vancomycin doses for pediatric patients, further studies 
are necessary to clarify the relationship between vancomycin 
trough levels and clinical efficacy, as well as the possibilities of 
nephrotoxicity in children.
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